C-TRIP: Targeted Gene Therapy for the Treatment of Heart Failure (P20)

C-TRIP:治疗心力衰竭的靶向基因治疗(P20)

基本信息

项目摘要

DESCRIPTION (provided by applicant): Despite the proliferation of therapies, congestive heart failure (HF) remains a progressive disease. There is therefore a desperate need for innovative rather than incremental therapies to reverse the course of ventricular dysfunction. Recent advances in understanding the molecular basis of myocardial dysfunction, together with the evolution of increasingly efficient gene transfer technology, have placed HF within reach of gene-based therapies. One of the key cellular alterations in both human and experimental HF is a defect in sarcoplasmic reticulum (SR) function, which is responsible for the abnormal intracellular Ca2+ handling observed in failing cardiomyocytes1-4 Deficient SR Ca2+ uptake during relaxation has been identified in failing hearts from both humans and animal models and has been associated with a decrease in the activity of the SR Ca2+-ATPase (SERCA2a), which is at least partially due to enhanced phospholamban (PLN) inhibition. Restoring SERCA2a levels or reducing PLN inhibition has been shown to improve function, metabolism and/or survival in a number of experimental models of heart failure. Over the last ten years, we have initiated and recently completed a first-in-man phase 1 clinical trial of gene therapy for heart failure using adeno-associated type 1 (AAV) vector carrying SERCA 2a5. The safety profile of AAV gene therapy along with the positive biological signals obtained from this phase 1 trial has led to the initiation of a phase 2 trial of AAV1.SERCA2a in NYHA class III/IV patients6. More recently, we have shown that by constitutively activating the inhibitor of protein phosphatase 1 (l-1) within the failing heart, there is improvement of SR Ca2+-handling, contractility and, most importantly, reversal of adverse remodeling by directly decreasing fibrosis and cardiac hypertrophy7-13. Even though AAV vectors have been proven to be safe in multiple trials including in patients with heart failure, their use for gene delivery has the following limitations: 1) they are not specific for the heart and 2) antecedent neutralizing antibodies to any individual serotype account for 40% of these patients which would need to be excluded from clinical trials14-17. We have therefore developed a cardiotropic chimeric of AAV that targets more specifically the heart and escapes the inherent immunity in patients. We, therefore, propose to take advantage of these novel chimeric vectors, which are also known as Bio Nano Particles (BNP), to directly target I-1 in experimental models of heart failure14-17. Within STAGE 1 of this proposal we will validate the target using this novel vector in a pre-clinical model of heart failure. In addition, we will analyze the prevalence of pre-existing neutralizing antibodies against our new cardiotropic vector in a heart failure patient population. In STAGE 2, we will carry out a phase 1, Open- Labeled, Dose-Escalation Trial of BNP111.sc-CMV.l1c by Intra-Coronary Infusion in Patients with Heart Failure followed by a A Phase 2, Randomized, Double-Blinded, Placebo-Controlled Dose Escalation Trial of Intra-Coronary Infusion of BNP111.sc-CMV.l1c in patients with heart failure. RELEVANCE (See instructions): Heart failure is a major cause of morbidity and mortality in the United States despite the novel therapies that are used to treat these patients. Gene therapy has emerged as a novel and viable strategy to target specific abnormalities in the failing heart. We have developed a cardiotropic Adeno-Associated Vector (AAV) that specifically targets the heart and escapes the inherent immunity in patients. This new cardiotropic vector combined with a novel well validated target offers a new strategy for the treatment of heart failure.
描述(由申请人提供):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Roger J. Hajjar其他文献

Structure-Based Design of Phospholamban Mutants for Gene Therapy
  • DOI:
    10.1016/j.bpj.2009.12.4188
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Simon J. Gruber;Kim N. Ha;Elizabeth L. Lockamy;Razvan L. Cornea;Roger J. Hajjar;Gianluigi Veglia;David D. Thomas
  • 通讯作者:
    David D. Thomas
1042. Tracking and Gene Expression Profile of Bone Marrow Mesenchymal Stem Cells Injected into Pig Myocardium by Magnetic Resonance Imaging and Laser-Capture Microdissection
  • DOI:
    10.1016/j.ymthe.2006.08.1138
  • 发表时间:
    2006-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Elie R. Chemaly;Irina Pomerantseva;Ryuichi Yoneyama;Djamel Lebeche;Davide Gianni;Kozo Hoshino;Yoshiaki Kawase;Federica del Monte;Roger J. Hajjar
  • 通讯作者:
    Roger J. Hajjar
AAV delivery strategy with mechanical support for safe and efficacious cardiac gene transfer in swine
具有机械支持的腺相关病毒递送策略用于猪的安全有效心脏基因转移
  • DOI:
    10.1038/s41467-024-54635-x
  • 发表时间:
    2024-12-01
  • 期刊:
  • 影响因子:
    15.700
  • 作者:
    Renata Mazurek;Serena Tharakan;Spyros A. Mavropoulos;Deanndria T. Singleton;Olympia Bikou;Tomoki Sakata;Taro Kariya;Kelly Yamada;Erik Kohlbrenner;Lifan Liang;Anjali J. Ravichandran;Shin Watanabe;Roger J. Hajjar;Kiyotake Ishikawa
  • 通讯作者:
    Kiyotake Ishikawa
Therapeutic Targeted Delivery of AAV9 Sh BNIP3 Reverses Cardiac Remodeling and Improves Diastolic and Systolic Function in a Rat Model of Pressure Overload Induced Heart Failure
  • DOI:
    10.1016/j.cardfail.2012.06.106
  • 发表时间:
    2012-08-01
  • 期刊:
  • 影响因子:
  • 作者:
    Antoine H. Chaanine;Ronald E. Gordon;Ludovic Benard;Erik Kohlbrenner;Roger J. Hajjar
  • 通讯作者:
    Roger J. Hajjar
Spectroscopic Design of Phospholamban Mutants to Treat Heart Failure
  • DOI:
    10.1016/j.bpj.2009.12.1337
  • 发表时间:
    2010-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Simon J. Gruber;Suzanne Haydon;Kim N. Ha;Roger J. Hajjar;Gianluigi Veglia;David D. Thomas
  • 通讯作者:
    David D. Thomas

Roger J. Hajjar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Roger J. Hajjar', 18)}}的其他基金

Small Molecule Therapy for the Treatment of Heart Failure
治疗心力衰竭的小分子疗法
  • 批准号:
    9335758
  • 财政年份:
    2017
  • 资助金额:
    $ 82.32万
  • 项目类别:
Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy
抗 AAV 抗体是心脏 AAV 基因治疗的障碍
  • 批准号:
    9281067
  • 财政年份:
    2016
  • 资助金额:
    $ 82.32万
  • 项目类别:
Anti-AAV Antibodies as an Obstacle to Cardiac AAV Gene Therapy
抗 AAV 抗体是心脏 AAV 基因治疗的障碍
  • 批准号:
    9176405
  • 财政年份:
    2016
  • 资助金额:
    $ 82.32万
  • 项目类别:
Role of miR25 in Heart Failure
miR25 在心力衰竭中的作用
  • 批准号:
    9249966
  • 财政年份:
    2015
  • 资助金额:
    $ 82.32万
  • 项目类别:
Role of miR25 in Heart Failure
miR25 在心力衰竭中的作用
  • 批准号:
    8914275
  • 财政年份:
    2015
  • 资助金额:
    $ 82.32万
  • 项目类别:
Treating Ventricle and Valve: New Synergies for Ischemic LV Remodeling with MR
治疗心室和瓣膜:MR 缺血性左室重塑的新协同作用
  • 批准号:
    9195751
  • 财政年份:
    2015
  • 资助金额:
    $ 82.32万
  • 项目类别:
Calcium Pump Activators for Heart Failure Therapy
用于心力衰竭治疗的钙泵激活剂
  • 批准号:
    9268662
  • 财政年份:
    2015
  • 资助金额:
    $ 82.32万
  • 项目类别:
Calcium Pump Activators for Heart Failure Therapy
用于心力衰竭治疗的钙泵激活剂
  • 批准号:
    9096874
  • 财政年份:
    2015
  • 资助金额:
    $ 82.32万
  • 项目类别:
SUMO1 and SERCA2a Function
SUMO1 和 SERCA2a 功能
  • 批准号:
    9087310
  • 财政年份:
    2013
  • 资助金额:
    $ 82.32万
  • 项目类别:
SUMO1 and SERCA2a Function
SUMO1 和 SERCA2a 功能
  • 批准号:
    8725733
  • 财政年份:
    2013
  • 资助金额:
    $ 82.32万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 82.32万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了